{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:42:36Z","timestamp":1756384956146,"version":"3.37.3"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T00:00:00Z","timestamp":1554163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T00:00:00Z","timestamp":1554163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009510","name":"University of Hull","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009510","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathol. Oncol. Res."],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s12253-019-00652-x","type":"journal-article","created":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T18:04:35Z","timestamp":1554228275000},"page":"985-995","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2276-0580","authenticated-orcid":false,"given":"Lily","family":"Oguh-Olayinka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dulani","family":"Ranatunge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Laufer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"Cawkwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Lind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,2]]},"reference":[{"key":"652_CR1","first-page":"718","volume":"34","author":"BP Lanphear","year":"1992","unstructured":"Lanphear BP, Buncher CR (1992) Latent period for malignant mesothelioma of occupational origin. J Occup Med 34:718\u2013721","journal-title":"J Occup Med"},{"key":"652_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1053\/sonc.2002.30227","volume":"29","author":"M Carbone","year":"2002","unstructured":"Carbone M, Kratzke RA, Testa JR (2002) The pathogenesis of mesothelioma. Semin Oncol 29:2\u201317","journal-title":"Semin Oncol"},{"key":"652_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0169-5002(01)00257-4","volume":"34","author":"GL Ceresoli","year":"2001","unstructured":"Ceresoli GL, Locati LD, Ferreri AJ et al (2001) Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer 34:279\u2013287","journal-title":"Lung Cancer"},{"key":"652_CR4","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/j.ejca.2005.04.019","volume":"41","author":"SL O\u2019Kane","year":"2005","unstructured":"O\u2019Kane SL, Cawkwell L, Campbell A, Lind MJ (2005) Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma. Eur J Cancer 41:1645\u20131648. \nhttps:\/\/doi.org\/10.1016\/j.ejca.2005.04.019","journal-title":"Eur J Cancer"},{"key":"652_CR5","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636\u20132644. \nhttps:\/\/doi.org\/10.1200\/JCO.2003.11.136","journal-title":"J Clin Oncol"},{"key":"652_CR6","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1200\/JCO.2008.19.8523","volume":"27","author":"AS Tsao","year":"2009","unstructured":"Tsao AS, Wistuba I, Roth JA, Kindler HL (2009) Malignant pleural mesothelioma. J Clin Oncol 27:2081\u20132090. \nhttps:\/\/doi.org\/10.1200\/JCO.2008.19.8523","journal-title":"J Clin Oncol"},{"key":"652_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ctrv.2009.09.003","volume":"36","author":"GL Ceresoli","year":"2010","unstructured":"Ceresoli GL, Zucali PA, Gianoncelli L, Lorenzi E, Santoro A (2010) Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev 36:24\u201332. \nhttps:\/\/doi.org\/10.1016\/j.ctrv.2009.09.003","journal-title":"Cancer Treat Rev"},{"key":"652_CR8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2217\/fon.12.14","volume":"8","author":"F Grosso","year":"2012","unstructured":"Grosso F, Scagliotti GV (2012) Systemic treatment of malignant pleural mesothelioma. Future Oncol 8:293\u2013305. \nhttps:\/\/doi.org\/10.2217\/fon.12.14","journal-title":"Future Oncol"},{"key":"652_CR9","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.2174\/138161205774370753","volume":"11","author":"J Cl\u00e0ria","year":"2005","unstructured":"Cl\u00e0ria J, Romano M (2005) Pharmacological intervention of cyclooxygenase-2 and 5-lipoxygenase pathways. Impact on inflammation and cancer. Curr Pharm Des 11:3431\u20133447. \nhttps:\/\/doi.org\/10.2174\/138161205774370753","journal-title":"Curr Pharm Des"},{"key":"652_CR10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/carcin\/bgp014","volume":"30","author":"A Greenhough","year":"2009","unstructured":"Greenhough A, Smartt HJM, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A (2009) The COX-2\/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30:377\u2013386. \nhttps:\/\/doi.org\/10.1093\/carcin\/bgp014","journal-title":"Carcinogenesis"},{"key":"652_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.molmed.2012.02.002","volume":"18","author":"MD Salvado","year":"2012","unstructured":"Salvado MD, Alfranca A, Haeggstr\u00f6m JZ, Redondo JM (2012) Prostanoids in tumor angiogenesis: therapeutic intervention beyond COX-2. Trends Mol Med 18:233\u2013243. \nhttps:\/\/doi.org\/10.1016\/j.molmed.2012.02.002","journal-title":"Trends Mol Med"},{"key":"652_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2174\/156802607779941369","volume":"7","author":"L Goossens","year":"2007","unstructured":"Goossens L, Pommery N, H\u00e9nichart JP (2007) COX-2\/5-LOX dual acting anti-inflammatory drugs in cancer chemotherapy. Curr Top Med Chem 7:283\u2013296","journal-title":"Curr Top Med Chem"},{"key":"652_CR13","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10555-011-9310-3","volume":"30","author":"C Schneider","year":"2011","unstructured":"Schneider C, Pozzi A (2011) Cyclooxygenases and lipoxygenases in cancer. Cancer Metastasis Rev 30:277\u2013294. \nhttps:\/\/doi.org\/10.1007\/s10555-011-9310-3","journal-title":"Cancer Metastasis Rev"},{"key":"652_CR14","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.3748\/wjg.v10.i13.1971","volume":"10","author":"S Fu","year":"2004","unstructured":"Fu S, Wu Y, Zhang Y, Qiao MM, Chen Y (2004) Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer. World J Gastroenterol 10:1971\u20131974","journal-title":"World J Gastroenterol"},{"key":"652_CR15","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.bcp.2011.06.028","volume":"82","author":"C Cerella","year":"2011","unstructured":"Cerella C, Sobolewski C, Chateauvieux S, Henry E, Schnekenburger M, Ghelfi J, Dicato M, Diederich M (2011) COX-2 inhibitors block chemotherapeutic agent-induced apoptosis prior to commitment in hematopoietic cancer cells. Biochem Pharmacol 82:1277\u20131290. \nhttps:\/\/doi.org\/10.1016\/j.bcp.2011.06.028","journal-title":"Biochem Pharmacol"},{"key":"652_CR16","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1001\/jama.294.8.914","volume":"294","author":"AT Chan","year":"2005","unstructured":"Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS (2005) Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 294:914\u2013923. \nhttps:\/\/doi.org\/10.1001\/jama.294.8.914","journal-title":"JAMA"},{"key":"652_CR17","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.lungcan.2009.04.008","volume":"67","author":"SL O\u2019Kane","year":"2010","unstructured":"O\u2019Kane SL, Eagle GL, Greenman J, Lind MJ, Cawkwell L (2010) COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines. Lung Cancer 67:160\u2013165. \nhttps:\/\/doi.org\/10.1016\/j.lungcan.2009.04.008","journal-title":"Lung Cancer"},{"key":"652_CR18","doi-asserted-by":"publisher","first-page":"e40794","DOI":"10.1371\/journal.pone.0040794","volume":"7","author":"UD Orlando","year":"2012","unstructured":"Orlando UD, Garona J, Ripoll GV, Maloberti PM, Solano \u00c1R, Avagnina A, Gomez DE, Alonso DF, Podest\u00e1 EJ (2012) The functional interaction between acyl-coa synthetase 4, 5-lipooxygenase and cyclooxygenase-2 controls tumor growth: a novel therapeutic target. PLoS One 7:e40794. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0040794","journal-title":"PLoS One"},{"issue":"2","key":"652_CR19","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3390\/ijms18020236","volume":"18","author":"Gillian Moore","year":"2017","unstructured":"Moore GY, Pidgeon GP (2017) Cross-talk between cancer cells and the tumour microenvironment: the role of the 5-lipoxygenase pathway. Int J Mol Sci 18","journal-title":"International Journal of Molecular Sciences"},{"key":"652_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrc2809","volume":"10","author":"D Wang","year":"2010","unstructured":"Wang D, DuBois R (2010) Eicosanoids and cancer. Nat Rev Cancer 10:181\u2013193. \nhttps:\/\/doi.org\/10.1038\/nrc2809","journal-title":"Nat Rev Cancer"},{"key":"652_CR21","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.bbrc.2005.07.166","volume":"335","author":"W-G Tong","year":"2005","unstructured":"Tong W-G, Ding X-Z, Talamonti MS, Bell RH, Adrian TE (2005) LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways. Biochem Biophys Res Commun 335:949\u2013956. \nhttps:\/\/doi.org\/10.1016\/j.bbrc.2005.07.166","journal-title":"Biochem Biophys Res Commun"},{"key":"652_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1254\/jphs.FP0060651","volume":"103","author":"A Ihara","year":"2007","unstructured":"Ihara A, Wada K, Yoneda M, Fujisawa N, Takahashi H, Nakajima A (2007) Blockade of leukotriene B4 signaling pathway induces apoptosis and suppresses cell proliferation in colon cancer. J Pharmacol Sci 103:24\u201332. \nhttps:\/\/doi.org\/10.1254\/jphs.FP0060651","journal-title":"J Pharmacol Sci"},{"key":"652_CR23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1098-8823(03)00042-X","volume":"71","author":"M Kandouz","year":"2003","unstructured":"Kandouz M, Nie D, Pidgeon GP, Krishnamoorthy S, Maddipati KR, Honn KV (2003) Platelet-type 12-lipoxygenase activates NF-kappaB in prostate cancer cells. Prostaglandins Other Lipid Mediat 71:189\u2013204","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"652_CR24","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1006\/excr.1994.1240","volume":"214","author":"KV Honn","year":"1994","unstructured":"Honn KV, Tim\u00e1r J, Rozhin J, Bazaz R, Sameni M, Ziegler G, Sloane BF (1994) A lipoxygenase metabolite, 12-(S)-HETE, stimulates protein kinase C-mediated release of cathepsin B from malignant cells. Exp Cell Res 214:120\u2013130. \nhttps:\/\/doi.org\/10.1006\/excr.1994.1240","journal-title":"Exp Cell Res"},{"key":"652_CR25","first-page":"2223","volume":"59","author":"SH Hong","year":"1999","unstructured":"Hong SH, Avis I, Vos MD, Mart\u00ednez A, Treston AM, Mulshine JL (1999) Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res 59:2223\u20132228","journal-title":"Cancer Res"},{"key":"652_CR26","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0002-9440(10)64198-3","volume":"161","author":"R Hennig","year":"2002","unstructured":"Hennig R, Ding X-Z, Tong W-G, Schneider MB, Standop J, Friess H, B\u00fcchler MW, Pour PM, Adrian TE (2002) 5-lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am J Pathol 161:421\u2013428. \nhttps:\/\/doi.org\/10.1016\/S0002-9440(10)64198-3","journal-title":"Am J Pathol"},{"key":"652_CR27","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/1097-0142(20010215)91:4<737::AID-CNCR1059>3.0.CO;2-F","volume":"91","author":"S Gupta","year":"2001","unstructured":"Gupta S, Srivastava M, Ahmad N, Sakamoto K, Bostwick DG, Mukhtar H (2001) Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer 91:737\u2013743. \nhttps:\/\/doi.org\/10.1002\/1097-0142(20010215)91:4<737::AID-CNCR1059>3.0.CO;2-F","journal-title":"Cancer"},{"key":"652_CR28","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1097\/01.ju.0000080296.54262.c8","volume":"170","author":"R Yoshimura","year":"2003","unstructured":"Yoshimura R, Matsuyama M, Tsuchida K et al (2003) Expression of lipoxygenase in human bladder carcinoma and growth inhibition by its inhibitors. J Urol 170:1994\u20131999. \nhttps:\/\/doi.org\/10.1097\/01.ju.0000080296.54262.c8","journal-title":"J Urol"},{"key":"652_CR29","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0952-3278(03)00110-8","volume":"69","author":"WG Jiang","year":"2003","unstructured":"Jiang WG, Douglas-Jones A, Mansel RE (2003) Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. Prostaglandins Leukot Essent Fat Acids 69:275\u2013281. \nhttps:\/\/doi.org\/10.1016\/S0952-3278(03)00110-8","journal-title":"Prostaglandins Leukot Essent Fat Acids"},{"key":"652_CR30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1053\/gast.2003.50011","volume":"124","author":"JF \u00d6hd","year":"2003","unstructured":"\u00d6hd JF, Nielsen CK, Campbell J, Landberg G, L\u00f6fberg H, Sj\u00f6lander A (2003) Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. Gastroenterology 124:57\u201370. \nhttps:\/\/doi.org\/10.1053\/gast.2003.50011","journal-title":"Gastroenterology"},{"key":"652_CR31","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/00008390-200209000-00003","volume":"12","author":"I Winer","year":"2002","unstructured":"Winer I, Normolle DP, Shureiqi I, Sondak VK, Johnson T, Su L, Brenner DE (2002) Expression of 12-lipoxygenase as a biomarker for melanoma carcinogenesis. Melanoma Res 12:429\u2013434. \nhttps:\/\/doi.org\/10.1097\/00008390-200209000-00003","journal-title":"Melanoma Res"},{"key":"652_CR32","doi-asserted-by":"publisher","first-page":"6703","DOI":"10.1158\/1078-0432.CCR-04-0838","volume":"10","author":"X Chen","year":"2004","unstructured":"Chen X, Wang S, Wu N, Sood S, Wang P, Jin Z, Beer DG, Giordano TJ, Lin Y, Shih WC, Lubet RA, Yang CS (2004) Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of Zileuton and celecoxib on carcinogenesis. Clin Cancer Res 10:6703\u20136709. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0838","journal-title":"Clin Cancer Res"},{"key":"652_CR33","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/carcin\/bgi026","volume":"26","author":"A Hoque","year":"2005","unstructured":"Hoque A, Lippman SM, Wu T-TT et al (2005) Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis 26:785\u2013791. \nhttps:\/\/doi.org\/10.1093\/carcin\/bgi026","journal-title":"Carcinogenesis"},{"key":"652_CR34","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/1078-0432.CCR-04-1684","volume":"11","author":"N Li","year":"2005","unstructured":"Li N, Sood S, Wang S, Fang M, Wang P, Sun Z, Yang CS, Chen X (2005) Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib. Clin Cancer Res 11:2089\u20132096. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-04-1684","journal-title":"Clin Cancer Res"},{"key":"652_CR35","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1096\/fj.01-0150com","volume":"15","author":"M Romano","year":"2001","unstructured":"Romano M, Catalano A, Nutini M et al (2001) 5-lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor. FASEB J 15:2326\u20132336. \nhttps:\/\/doi.org\/10.1096\/fj.01-0150com","journal-title":"FASEB J"},{"key":"652_CR36","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1136\/gut.45.3.409","volume":"45","author":"L Cawkwell","year":"1999","unstructured":"Cawkwell L, Gray S, Murgatroyd H, Sutherland F, Haine L, Longfellow M, O'Loughlin S, Cross D, Kronborg O, Fenger C, Mapstone N, Dixon M, Quirke P (1999) Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair. Gut 45:409\u2013415. \nhttps:\/\/doi.org\/10.1136\/gut.45.3.409","journal-title":"Gut"},{"key":"652_CR37","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/bcpt.12114","volume":"114","author":"D Steinhilber","year":"2014","unstructured":"Steinhilber D, Hofmann B (2014) Recent advances in the search for novel 5-lipoxygenase inhibitors. Basic Clin Pharmacol Toxicol 114:70\u201377. \nhttps:\/\/doi.org\/10.1111\/bcpt.12114","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"652_CR38","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.tips.2007.11.006","volume":"29","author":"JF Evans","year":"2008","unstructured":"Evans JF, Ferguson AD, Mosley RT, Hutchinson JH (2008) What\u2019s all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. Trends Pharmacol Sci 29:72\u201378. \nhttps:\/\/doi.org\/10.1016\/j.tips.2007.11.006","journal-title":"Trends Pharmacol Sci"},{"key":"652_CR39","doi-asserted-by":"publisher","first-page":"4295","DOI":"10.1016\/j.bmc.2006.01.057","volume":"14","author":"JD Deschamps","year":"2006","unstructured":"Deschamps JD, Kenyon VA, Holman TR (2006) Baicalein is a potent in vitro inhibitor against both reticulocyte 15-human and platelet 12-human lipoxygenases. Bioorg Med Chem 14:4295\u20134301. \nhttps:\/\/doi.org\/10.1016\/j.bmc.2006.01.057","journal-title":"Bioorg Med Chem"},{"key":"652_CR40","first-page":"625","volume":"55","author":"DL DeWitt","year":"1999","unstructured":"DeWitt DL (1999) Cox-2-selective inhibitors: the new super aspirins. Mol Pharmacol 55:625\u2013631","journal-title":"Mol Pharmacol"},{"key":"652_CR41","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1124\/dmd.108.020347","volume":"36","author":"W Albrecht","year":"2008","unstructured":"Albrecht W, Unger A, Nussler AK, Laufer S (2008) In vitro metabolism of 2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] acetic acid (licofelone, ML3000), an inhibitor of cyclooxygenase-1 and -2 and 5-lipoxygenase. Drug Metab Dispos 36:894\u2013903. \nhttps:\/\/doi.org\/10.1124\/dmd.108.020347","journal-title":"Drug Metab Dispos"},{"key":"652_CR42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"T-C Chou","year":"1984","unstructured":"Chou T-C, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul 22:27\u201355. \nhttps:\/\/doi.org\/10.1016\/0065-2571(84)90007-4","journal-title":"Adv Enzym Regul"},{"key":"652_CR43","first-page":"1857","volume":"8","author":"JG Edwards","year":"2002","unstructured":"Edwards JG, Faux SP, Plummer SM et al (2002) Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma n. Clin Cancer Res 8:1857\u20131862","journal-title":"Clin Cancer Res"},{"key":"652_CR44","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1136\/thx.2003.008912","volume":"59","author":"A Baldi","year":"2004","unstructured":"Baldi A (2004) Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma. Thorax 59:428\u2013433. \nhttps:\/\/doi.org\/10.1136\/thx.2003.008912","journal-title":"Thorax"},{"key":"652_CR45","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ejcts.2010.02.012","volume":"38","author":"TC Mineo","year":"2010","unstructured":"Mineo TC, Ambrogi V, Cufari ME, Pompeo E (2010) May cyclooxygenase-2 (COX-2), p21 and p27 expression affect prognosis and therapeutic strategy of patients with malignant pleural mesothelioma? Eur J Cardiothorac Surg 38:245\u2013252. \nhttps:\/\/doi.org\/10.1016\/j.ejcts.2010.02.012","journal-title":"Eur J Cardiothorac Surg"},{"key":"652_CR46","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1158\/1535-7163.MCT-12-1103","volume":"12","author":"B Nuvoli","year":"2013","unstructured":"Nuvoli B, Galati R (2013) Cyclooxygenase-2, epidermal growth factor receptor, and aromatase signaling in inflammation and mesothelioma. Mol Cancer Ther 12:844\u2013852. \nhttps:\/\/doi.org\/10.1158\/1535-7163.MCT-12-1103","journal-title":"Mol Cancer Ther"},{"key":"652_CR47","first-page":"959","volume":"25","author":"HZ Lee","year":"2005","unstructured":"Lee HZ, Leung HWC, Lai MY, Wu CH (2005) Baicalein induced cell cycle arrest and apoptosis in human lung squamous carcinoma CH27 cells. Anticancer Res 25:959\u2013964","journal-title":"Anticancer Res"},{"key":"652_CR48","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1158\/1535-7163.MCT-07-0281","volume":"6","author":"J-I Chao","year":"2007","unstructured":"Chao J-I, Su W-C, Liu H-F (2007) Baicalein induces cancer cell death and proliferation retardation by the inhibition of CDC2 kinase and survivin associated with opposite role of p38 mitogen-activated protein kinase and AKT. Mol Cancer Ther 6:3039\u20133048. \nhttps:\/\/doi.org\/10.1158\/1535-7163.MCT-07-0281","journal-title":"Mol Cancer Ther"},{"key":"652_CR49","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.bbamcr.2011.05.003","volume":"1813","author":"H Takahashi","year":"2011","unstructured":"Takahashi H, Chen MC, Pham H, Angst E, King JC, Park J, Brovman EY, Ishiguro H, Harris DM, Reber HA, Hines OJ, Gukovskaya AS, Go VLW, Eibl G (2011) Baicalein, a component of Scutellaria baicalensis, induces apoptosis by Mcl-1 down-regulation in human pancreatic cancer cells. Biochim Biophys Acta 1813:1465\u20131474. \nhttps:\/\/doi.org\/10.1016\/j.bbamcr.2011.05.003","journal-title":"Biochim Biophys Acta"},{"key":"652_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0072927","volume":"8","author":"K Chen","year":"2013","unstructured":"Chen K, Zhang S, Ji Y, Li J, An P, Ren H, Liang R, Yang J, Li Z (2013) Baicalein inhibits the invasion and metastatic capabilities of hepatocellular carcinoma cells via down-regulation of the ERK pathway. PLoS One 8:e72927. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0072927","journal-title":"PLoS One"},{"key":"652_CR51","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/carcin\/bgm265","volume":"29","author":"S Tavolari","year":"2008","unstructured":"Tavolari S, Bonaf\u00e8 M, Marini M, Ferreri C, Bartolini G, Brighenti E, Manara S, Tomasi V, Laufer S, Guarnieri T (2008) Licofelone, a dual COX\/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. Carcinogenesis 29:371\u2013380. \nhttps:\/\/doi.org\/10.1093\/carcin\/bgm265","journal-title":"Carcinogenesis"},{"key":"652_CR52","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/j.1476-5381.2010.00915.x","volume":"161","author":"AS Fischer","year":"2010","unstructured":"Fischer AS, Metzner J, Steinbrink SD, Ulrich S, Angioni C, Geisslinger G, Steinhilber D, Maier TJ (2010) 5-lipoxygenase inhibitors induce potent anti-proliferative and cytotoxic effects in human tumour cells independently of suppression of 5-lipoxygenase activity. Br J Pharmacol 161:936\u2013949. \nhttps:\/\/doi.org\/10.1111\/j.1476-5381.2010.00915.x","journal-title":"Br J Pharmacol"},{"key":"652_CR53","doi-asserted-by":"publisher","first-page":"4644","DOI":"10.1111\/febs.12969","volume":"281","author":"P Aryal","year":"2014","unstructured":"Aryal P, Kim K, Park P-H, Ham S, Cho J, Song K (2014) Baicalein induces autophagic cell death through AMPK\/ULK1 activation and downregulation of mTORC1 complex components in human cancer cells. FEBS J 281:4644\u20134658. \nhttps:\/\/doi.org\/10.1111\/febs.12969","journal-title":"FEBS J"},{"key":"652_CR54","doi-asserted-by":"publisher","first-page":"6525","DOI":"10.1158\/1078-0432.CCR-07-4631","volume":"14","author":"LG Melstrom","year":"2008","unstructured":"Melstrom LG, Bentrem DJ, Salabat MR, Kennedy TJ, Ding XZ, Strouch M, Rao SM, Witt RC, Ternent CA, Talamonti MS, Bell RH, Adrian TA (2008) Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clin Cancer Res 14:6525\u20136530. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4631","journal-title":"Clin Cancer Res"},{"key":"652_CR55","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/1097-0215(20000701)87:1<37::AID-IJC6>3.0.CO;2-L","volume":"87","author":"J Tim\u00e1r","year":"2000","unstructured":"Tim\u00e1r J, R\u00e1s\u00f3 E, D\u00f6me B, Li L, Grignon D, Nie D, Honn KV, Hagmann W (2000) Expression, subcellular localization and putative function of platelet-type 12-lipoxygenase in human prostate cancer cell lines of different metastatic potential. Int J Cancer 87:37\u201343. \nhttps:\/\/doi.org\/10.1002\/1097-0215(20000701)87:1<37::AID-IJC6>3.0.CO;2-L","journal-title":"Int J Cancer"},{"key":"652_CR56","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jep.2014.08.031","volume":"156","author":"M Li","year":"2014","unstructured":"Li M, Shi A, Pang H, Xue W, Li Y, Cao G, Yan B, Dong F, Li K, Xiao W, He G, Du G, Hu X (2014) Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects. J Ethnopharmacol 156:210\u2013215. \nhttps:\/\/doi.org\/10.1016\/j.jep.2014.08.031","journal-title":"J Ethnopharmacol"}],"container-title":["Pathology &amp; Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-019-00652-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12253-019-00652-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-019-00652-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T13:18:35Z","timestamp":1590067115000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12253-019-00652-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,2]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["652"],"URL":"https:\/\/doi.org\/10.1007\/s12253-019-00652-x","relation":{},"ISSN":["1219-4956","1532-2807"],"issn-type":[{"type":"print","value":"1219-4956"},{"type":"electronic","value":"1532-2807"}],"subject":[],"published":{"date-parts":[[2019,4,2]]},"assertion":[{"value":"1 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"None to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}